Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Tipranks - Tipranks - Wed Apr 8, 1:38AM CDT

In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00.

Easter Sale - 70% Off TipRanks

According to TipRanks, Ebrahim is an analyst with an average return of -12.3% and a 23.08% success rate.

In addition to J.P. Morgan, GlaxoSmithKline also received a Sell from Barclays’s James Gordon CFA in a report issued today. However, on April 2, Jefferies maintained a Buy rating on GlaxoSmithKline (LSE: GSK).

See Insiders’ Hot Stocks on TipRanks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million

Based on the recent corporate insider activity of 324 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.

Read More on GB:GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).